Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sipcam pacific australia pty. limited - oryzalin - suspension concentrate - oryzalin anilide/aniline-dinitro active 500.0 g/l - herbicide - almond | amenity plantings | apple | apricot | banana | cherry | common couch lawn or turf | conifer - seedling stage | grape | - barnyard grass or water grass | barnyard or water grass | blackberry nightshade | caltrop or yellow vine | chickweed | deadnettle | fat hen | fumitory | guinea grass | lovegrass | paddy melon | paradoxa grass | pigeon grass | pigweed spp. | ryegrass | silverleaf nightshade | sow or milk thistle | spiny burrgrass, innocent weed | summer or crab grass | winter grass | wireweed, knotweed or hogweed | annual blue grass | annual lovegrass | annual phalaris | annual pigweed | annual poa | annual summer grass | barnyard grass | bindy-eye | black nightshade | bullhead | bull's head | caltrop burr | canary grass | cathead | cat's-head | common chickweed | common sowthistle | fallopia aviculare | gentle annie | goat's-head | goose grass | gooseberry melon | hedgehog grass | henbit deadnettle | munyeroo | nightshade | pigeon weed | pink weed | portulaca oleracea | prickly paddy melon | puncture vine | purple pigeon grass | purslane | setaria gracilis | setaria pallidefusca | setaria porphyrantha | setaria pumila | setar

New Zealand - English - Ministry for Primary Industries

adria new zealand ltd - tebufenozide - tebufenozide 250 g/litre - insecticide

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 10 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; mannitol; pregelatinised maize starch; crospovidone; sodium lauryl sulfate; aspartame; colloidal anhydrous silica; magnesium stearate; guar gum - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 5 mg - tablet, orally disintegrating - excipient ingredients: microcrystalline cellulose; mannitol; pregelatinised maize starch; crospovidone; sodium lauryl sulfate; aspartame; colloidal anhydrous silica; magnesium stearate; guar gum - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 10 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 400 - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; hyprolose; titanium dioxide; hypromellose; macrogol 4000; sodium citrate dihydrate - treatment of schizophrenia and related psychoses. short-term treatment, alone or in combination with lithium or valproate, of acute manic episodes associated with bipolar i disorder. preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 15 mg - tablet, orally disintegrating - excipient ingredients: purified talc; colloidal anhydrous silica; crospovidone; hyprolose; magnesium stearate; lactose monohydrate; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - olanzapine, quantity: 20 mg - tablet, orally disintegrating - excipient ingredients: magnesium stearate; hyprolose; colloidal anhydrous silica; purified talc; lactose monohydrate; crospovidone; flavour - for the treatment of schizophrenia and related psychoses. ,alone or in combination with lithium or valproate, it is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. ,for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.